The lab of The Wistar Institute’s Jessie Villanueva has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. The team published their findings in the paper at the journal Science Translational Medicine.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.
